Marshall Wace LLP Raises Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Marshall Wace LLP raised its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 94.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 4,303,596 shares of the biopharmaceutical company's stock after purchasing an additional 2,087,635 shares during the period. Marshall Wace LLP owned approximately 2.27% of Esperion Therapeutics worth $9,554,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. BOKF NA bought a new position in Esperion Therapeutics during the second quarter valued at $26,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics during the 2nd quarter worth $28,000. CVI Holdings LLC bought a new stake in Esperion Therapeutics in the 1st quarter valued at about $37,000. State Board of Administration of Florida Retirement System bought a new stake in Esperion Therapeutics in the 1st quarter valued at about $50,000. Finally, National Bank of Canada FI lifted its holdings in Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ESPR shares. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 12th. Bank of America downgraded Esperion Therapeutics from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. StockNews.com cut Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday. Finally, Needham & Company LLC dropped their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.17.

Esperion Therapeutics Trading Down 1.8 %

Shares of ESPR traded down $0.03 during mid-day trading on Monday, reaching $1.65. 2,771,097 shares of the stock traded hands, compared to its average volume of 6,518,907. Esperion Therapeutics, Inc. has a 1 year low of $0.70 and a 1 year high of $3.40. The company has a market cap of $312.61 million, a price-to-earnings ratio of -1.67 and a beta of 1.00. The firm has a fifty day moving average price of $1.90 and a 200 day moving average price of $2.20.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. On average, sell-side analysts anticipate that Esperion Therapeutics, Inc. will post -0.04 EPS for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.